Sagimet Biosciences Inc(SGMT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 AM ET (Korea 10/29 17:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.28 | Insider Own | 7.47% | Shs Outstand | 70.9M | Perf Week | 7.51% |
| Market Cap | 0.76B | Forward P/E | - | EPS next Y | -19.27% | Insider Trans | -8.12% | Shs Float | 65.6M | Perf Month | 15.11% |
| Enterprise Value | 0.52B | PEG | - | EPS next Q | -0.26 | Inst Own | 74.08% | Short Float | 17.57% | Perf Quarter | 46.92% |
| Income | -0.05B | P/S | - | EPS this Y | 28.71% | Inst Trans | 112.28% | Short Ratio | 8.75 | Perf Half Y | 24.88% |
| Sales | 0.00B | P/B | 2.59 | EPS next 5Y | -0.08% | ROA | -23.49% | Short Interest | 11.53M | Perf YTD | 81.42% |
| Book/sh | 4.15 | P/C | 3.15 | EPS past 3/5Y | -3.41% -24.29% | ROE | -24.37% | 52W High | -6.19% ($11.45) | Perf Year | 30.34% |
| Cash/sh | 3.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -18.25% | 52W Low | 138.67% ($4.50) | Perf 3Y | 189.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 30.54% | Gross Margin | - | Volatility(W/M) | 5.58% 7.03% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 44.94 | EPS Q/Q | 18.57% | Profit Margin | - | RSI (14) | 62.44 | Recom | 1.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 44.94 | Sales Q/Q | - | SMA20 | 17.77% ($9.12) | Beta | 3.48 | Target Price | $27.92 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/11 | SMA50 | 8.04% ($9.94) | Rel Volume | 0.94 | Prev Close | $10.42 |
| Employees | 16 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -3.59% - | SMA200 | 44.01% ($7.46) | Avg Volume(3M) | 1.32M | Price | $10.74 |
| IPO | 2023/7/14 | Option/Short | Yes/Yes | Trades | 7426 | Volume | 1,235,573 | Change | 3.07% |
A US clinical-stage biotech company developing fatty acid synthase (FAS) inhibitors. Its lead candidate is denifanstat, an oral drug primarily targeting metabolic dysfunction-associated steatohepatitis (MASH), with efforts underway to expand its application into areas such as acne and oncology.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded about as much as usual. That is 94% of its average volume.
SGMT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +28.7% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +189.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 74.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #183 of 594 in the industry
Based on market cap of $755M.
ARDX#180 Ardelyx Inc $772M PER - 
OABI#181 OmniAb Inc $768M PER - 
ANNX#182 Annexon Inc $766M PER - SGMT#183 Sagimet Biosciences Inc $755M PER - 
GYRE#184 Gyre Therapeutics Inc $752M PER - 
FAQ
What kind of company is SGMT?
SGMT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SGMT?
The market cap of SGMT is approximately $755M, ranking 2,812 within its sector.
What is the 52-week high and low for SGMT?
SGMT has recorded a 52-week high of $11.45 and a low of $4.50.
